Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 18 of 18

List	Outcome	Time frame	Description
Primary	Skin 11β-HSD1 activity	Change between day 0 and day 28	Enzyme activity radioassay to evaluate AZD4107 efficacy in skin
Secondary	Urinary cortisol / cortisone metabolites	Change between day 0 and day 35	Urine samples for tetrahydrocortisol / tetrahydrocortisone metabolite ratios to evaluate systemic AZD4107 efficacy
Secondary	AZD4017 in plasma	Change between day 0 and day 28	Quantification of AZD4017 concentration in plasma to evaluate systemic AZD4107 exposure
Secondary	AZD4017 in skin	Change between day 0 and day 28	Quantification of AZD4017 concentration in plasma to evaluate skin AZD4107 exposure
Secondary	Discontinuation due to Adverse Event	Day 42	Adverse Event-related participant withdrawals to evaluate safety
Secondary	Body mass index	Change between day 0 and day 35	Body mass index to evaluate safety
Secondary	Waist-hip ratio	Change between day 0 and day 35	Waist-hip ratio to evaluate safety
Secondary	Blood pressure (sphygmomanometer)	Change between day 0 and day 35	Blood pressure to evaluate safety
Secondary	Sudomotor function	Change between day 0 and day 35	Conducted with a Sudoscan device to measure c-fiber innervation in hands and feet for skin function
Secondary	Skin hydration	Change between day 0 and day 35	Conducted with a Corneometer device to measure skin water content for skin function
Secondary	Epidermal barrier function	Change between day 0 and day 35	Conducted with a Tewameter device to measure skin trans-epidermal water loss for skin function
Secondary	Epidermal barrier integrity	Change between day 0 and day 28	Conducted by tape tripping to a pre-determined trans-epidermal water loss rate for skin function
Secondary	Skin thickness	Change between day 0 and day 35	Conducted by Optical Coherence Tomography imaging for skin function
Secondary	Wound healing	Change between day 0 and day 2	Conducted by Optical Coherence Tomography imaging for skin function
Secondary	Wound healing	Change between day 0 and day 7	Conducted by Optical Coherence Tomography imaging for skin function
Secondary	Wound healing	Change between day 28 and day 30	Conducted by Optical Coherence Tomography imaging for skin function
Secondary	Wound healing	Change between day 28 and day 35	Conducted by Optical Coherence Tomography imaging for skin function
Secondary	Skin RNA-seq gene expression profiling	Change between day 0 and day 28	For skin function

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03313297/registered

API reference For AI assistants